Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib drug-drug interaction study with transporter substrates in healthy volunteers
NCT05064488Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of evobrutinib (2 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity at Day 10 and Maximum Observed Plasma Concentration at Day 10. Started Oct 2021; status: completed.
02
Drugs
evobrutinib
Beyond the preview
Go deeper on NCT05064488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064488.